SCHEMBL4881292

SCHEMBL4881292

O=S(=O)(Cl)c1ccc(Nc2ccnc(Cl)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 11/20 0.54
CA1 P00915 10/20 0.54
CA12 O43570 3/20 0.54
CA9 Q16790 2/20 0.54
CA14 Q9ULX7 2/20 0.54
ROCK1 Q13464 2/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
AURKA O14965 4/20 0.46
AURKB Q96GD4 2/20 0.46
CDK2 P24941 1/20 0.42
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
ALOX12 P18054 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5394104 0.78 EPHB4 (0.45) ROCK1AURKACDK2MEN1NPC1
SCHEMBL5443900 0.78 SCN9A (0.51) CA2CA1CA12CA9CA14
SCHEMBL5263722 0.78 PIK3CA (0.48) CA2CA1CA12ROCK1AURKA
SCHEMBL3302653 0.78 LMNA (0.67) AURKACDK2MEN1NPC1LMNA
SCHEMBL13392205 0.78 NPC1 (0.75) CA2CA1AURKAAURKBCDK2
SCHEMBL3988183 0.78 AURKA (0.65) ROCK1AURKAAURKBCDK2MEN1
SCHEMBL4767203 0.78 NPC1 (0.46) CA2CA1CA12CA9CA14
SCHEMBL4251644 0.77 IKBKB (0.52) CA2CA1CA12CA9CA14
Hydrochloric Acid SCHEMBL2177469 0.77 ROCK1 (0.68) ROCK1AURKAAURKBMEN1NPC1
Hydrochloric Acid SCHEMBL3299181 0.77 NPC1 (0.73) CA2CA1AURKAAURKBCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE CA2 3293/4885CA1 4640/4885CA12 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.